tbuckley/cabot-search huggingface dataset:
OP0153-PARE Reumamama's en –Papa's: Info Sessions for (Future) Parents with Rmds and for Parents with Children with Juvenile Arthritis
Authors: A. Marchal, I. De Keyser
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> When diagnosed with a rheumatic condition (RMD), the first concern is managing and controlling the disease. More specific topics such as how you deal with a diagnosis as a parent of a child with an RMD or how to take care of children as a young parent with an RMD are less discussed with the rheumatologist. A lot of questions and concerns about heredity and pregnancy stay unanswered too. <h3>Objectives</h3> ReumaNet wants to offer tailor made information for young people with an RMD and a child wish and for parents of a child with an RMD. <h3>Methods</h3> ReumaNet, the Flemish organisation for people with RMDs, organised two info sessions in September-November 2015. The two target groups were 1) young (future) parents with an RMD and 2) parents with a child with an RMD. Both target groups first met informally for sharing their personal stories, concerns, experiences and expectations. During this first meeting, they noted down several questions and concerns regarding the topic. During the second session, different specialists such as a rheumatologist, a psychologist, a gynecologist, a pediatrician, … tried to answer these specific questions and they gave more information on pregnancy and RMD9s in the first group, and RMD9s in children in the other group. <h3>Results</h3> Both sessions were well attended, although more people showed up during the second session. People obviously feel more safe when they mainly have to listen to information, instead of participating in a discussion. (Future) parents with an RMD received information regarding heredity, pregnancy, delivery, (breast)feeding and practical tips and tricks regarding taking care of children. Parents with children with an RMD received not only practical information concerning juvenile arthritis (the diagnosis, the disease, future perspectives and impact in school), but also information regarding the psychological impact of receiving and dealing with the diagnosis as a parent. <h3>Conclusions</h3> There is a great need for information for either young parents with an RMD as well as for parents of a child with an RMD. Furthermore, these two groups will always be renewed throughout the years. This means the need for this kind of information will be ongoing. Along with organising ReuMaMaMa9s, ReumaNet is also developing three brochures on these topics: "Pregnancy and heredity", "How to take care of infants", for parents with a RMD9 and "Juvenile Arthritis". The live sessions will be repeated every two years. <h3>Disclosure of Interest</h3> None declared
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Authors: Lucia Nogova, Lecia V. Sequist, Jose Manuel Perez Garcia, Fabrice Andre, Jean-Pierre Delord, Manuel Hidalgo, Jan H.M. Schellens, Philippe A. Cassier, D. Ross Camidge, Martin Schuler, Ulka Vaishampayan, Howard A. Burris, G. Gary Tian, Mario Campone, Zev A. Wainberg, Wan-Teck Lim, Patricia LoRusso, Geoffrey I. Shapiro, Katie Parker, Xueying Chen, Somesh Choudhury, Francois Ringeisen, Diana Graus-Porta, Dale Porter, Randi Isaacs, Reinhard Buettner, Jürgen Wolf
Journal: Journal of Clinical Oncology (2017)

Purpose This two-part, first-in-human study was initiated in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors (FGFRs) to determine the maximum tolerated dose (MTD), the recommended phase II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 tyrosine kinase inhibitor. Patients and Methods Adult patients were treated with escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day cycles. During expansion at the MTD, patients with FGFR1-amplified squamous cell non-small-cell lung cancer (sqNSCLC; arm 1) or other solid tumors with FGFR genetic alterations (mutations/amplifications/fusions) received BGJ398 daily on a continuous schedule (arm 2), or on a 3-weeks-on/1-week-off schedule (arm 3). Results Data in 132 patients from the escalation and expansion arms are reported (May 15, 2015, cutoff). The MTD, 125 mg daily, was determined on the basis of dose-limiting toxicities in four patients (100 mg, grade 3 aminotransferase elevations [n = 1]; 125 mg, hyperphosphatemia [n = 1]; 150 mg, grade 1 corneal toxicity [n = 1] and grade 3 aminotransferase elevations [n = 1]). Common adverse events in patients treated at the MTD (n = 57) included hyperphosphatemia (82.5%), constipation (50.9%), decreased appetite (45.6%), and stomatitis (45.6%). A similar safety profile was observed using the 3-weeks-on/1-week-off schedule (RP2D). However, adverse event-related dose adjustments/interruptions were less frequent with the 3-weeks-on/1-week-off (50.0%) versus the continuous (73.7%) schedule. Antitumor activity (seven partial responses [six confirmed]) was demonstrated with BGJ398 doses ≥ 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancer. Conclusion BGJ398 at the MTD/RP2D had a tolerable and manageable safety profile and showed antitumor activity in several tumor types, including FGFR1-amplified sqNSCLC and FGFR3-mutant bladder/urothelial cancers.
Phase III Study of Immunotherapy with Recombinant Interleukin-2 (IL-2) Versus No Further Therapy in Acute Myeloid Leukemia (AML) Patients ≥ 60 Years in First Complete Remission (CALGB 9720).
Authors: Maria R. Baer, Stephen L. George, Michael A. Caligiuri, Ben L. Sanford, Kieran L. O’Loughlin, Krysztof Mrozek, Jonathan E. Kolitz, Bayard L. Powell, Joseph O. Moore, Richard M. Stone, Clara D. Bloomfield, Richard A. Larson
Journal: Blood (2006)
RNA-Seq Expression Profiling of AML Stem Cells Reveals Differential Expression of Lineage Differentiation Markers and Novel Splice Variants.
Authors: Benjamin G Vincent, Darshan Singh, Michael Wu, Sally A. Hunsucker, Gheath Alatrash, Kathryn Ruisaard, Pariya Sukhumalchandra, Karen Clise-Dwyer, Jonathan S Serody, Jan F Prins, Jeffrey J. Molldrem, Paul M. Armistead
Journal: Blood (2012)
Analysis of Immunoglobulin Gene Mutation Status in Lymphoplasmacytic and Splenic Marginal Zone Lymphomas with Bone Marrow Infiltration.
Authors: Gachard Nathalie, Parrens Marie, Petit Barbara, Soubeyran Isabelle, Costes Valerie, Brousset Pierre, Cogne Michel, Bordessoule Dominique, Feuillard Jean
Journal: Blood (2006)
A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis or Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib: The ‘START-L’ CA180015 Study.
Authors: Oliver G. Ottmann, G. Martinelli, H. Dombret, H. Kantarjian, A. Hochhaus, B. Simonsson, A. Aloe, A. Apanovitch, N. Shah
Journal: Blood (2005)
AB1071 How Much Is The Awareness about Rheumatology? Survey among Medical Students (Yr 3) in Velammal Medical College, Madurai, Tamilnadu, India:
Authors: S. Nallasivan
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatology is a fascinating medical subspeciality. Over 200 syndromes and diagnosis have been described in rheumatology and recently lot of thrust has been given to improve the Rheumatology both in government and private sectors in health care in India. Rheumatology as super specialty in India is slowly gaining prominence, however public awareness still needs to improve. <h3>Objectives</h3> 1. To assess the awareness of rheumatology and musculoskeletal health among the medical students (year 3). 2. To gain insight in to their knowledge about this medical subspecialty, in order to improve their educational tools and sessions, which inturn will shape up the changes in their curriculum.(MBBS) <h3>Methods</h3> This survey was conducted as anonymised questionnaire. All 3rd yr medical students were requested to express their opinion while answering on a scale of 1 to 10. <h3>Results</h3> 118 students participated in this survey and answered 10 questions: <h3>Conclusions</h3> Although this is the first of its kind, young medical students have insights in to the rheumatology around the world. They are aware about the multisystem nature of the diseases, research benefits and support to the charities. We are aware about their interests. We need to improve the access to rheumatology education and help our patients. There has been increasing awareness about the EULAR/BSR/ACR/APLAR- the four big leagues around the world, which guide the patients and medical professionals in Rheumatology <h3>Acknowledgement</h3> Special acknowledgement to all the year 3 medical students. <h3>Disclosure of Interest</h3> None declared
PTU-081 CD151 In Chronic Liver Disease and HCC - A New Player in T Cell Recruitment to The Liver
Authors: JCR Wadkin, DA Patten, SK Kamarajah, C Weston, S Shetty
Journal: Gut (2016)

<h3>Introduction</h3> Inflammation of the liver drives the onset and progression of chronic liver diseases whilst fostering an environment where the formation of neoplastic tumours such as hepatocellular carcinomas (HCC) can occur. A key step in this process is leukocyte recruitment via hepatic sinusoidal endothelial cells. CD151, a member of the tetraspanin family, has been shown to regulate heterotypic partner proteins involved in leukocyte recruitment and therefore an understanding of the expression and function of CD151 in the liver could identify new organ-specific anti-inflammatory therapies. <h3>Methods</h3> We used immunohistochemistry, dual colour immunofluorescence co-localisation studies, qRT-PCR and western blotting to determine the cell specific expression of CD151 in pathological control liver, chronic liver diseases and tissue taken from patients with HCC. Cell-based ELISA, qRT-PCR and western blotting were then used to determine the regulation of CD151 expression by hepatic sinusoidal endothelial cells (HSEC) following growth factor and cytokine treatment to mimic inflammatory and tumourigenic environments. Flow-based adhesion assays were used to study the role of CD151 in the adhesion of Jurkat cells, a human T cell line, to HSEC monolayers with subsequent immunofluorescence analysis. <h3>Results</h3> Increased CD151 protein expression was associated with areas of fibrosis and neovascularisation, particularly in parenchymal liver disease such as alcoholic and non-alcoholic fatty liver disease as well as in HCC. CD151 was highly expressed by HSEC both within liver tissue and <i>in vitro</i>. The expression of CD151 in HSEC was upregulated by stimulation with tumour cell line supernatant or a combination of hepatocyte and vascular endothelial growth factors. We found CD151 molecules clustering around adherent Jurkat cells following capture from flow by HSEC monolayers. Function-blocking antibodies to CD151 significantly reduced adherence of Jurkat under conditions of shear stress. <h3>Conclusion</h3> We demonstrate for the first time the expression of CD151 on human sinusoidal endothelial cells and that this molecule is expressed in neovessels in chronic liver disease and HCC. We also demonstrate that CD151 is upregulated by pro-tumourigenic factors on HSEC and functionally plays a role in T cell adhesion to HSEC. These findings further our understanding of liver inflammation and lymphocyte recruitment to the organ, in both chronic and malignant disease, and could form the basis of a potential therapeutic target. <h3>Disclosure of Interest</h3> None Declared
THU0089 Rheumatoid Arthritis and Periodontal Disease in Algerian People
Authors: C. Dahou, F. Mechid, S. Salah, M. Meddad, S. Merad
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Introduction</h3> Rheumatoid arthritis (RA) and periodontitis (PD) are two chronic inflammatory affections that share many similarities. Many studies report the increased frequency of periodontitis during rheumatoid arthritis. The porphyromonas gingivalis, periodontopathogenic bacterium plays a main role through peptidylarginine-deiminase an enzyme capable of citrullinating endogenous proteins and generates an autoimmune reaction. <h3>Objectives</h3> The aim of this study was to determine the prevalence of periodontitis during rheumatoid arthritis and its relationship with RA severity, treatment and patient characteristics. <h3>Methods</h3> This is a multicentre,cross-sectional, prospective study. Were included adults RA. We identified sociodemographic factors, the periodontal disease status and anaerobic germs, clinical activity of RA with the Disease activity score (DAS 28-VS), the Health Assessment Questionnaire (HAQ), extraarticular manifestations, Sharp Score and periodontal anaerobic bacteria. Were determined correlations between PD and patient characteristics, treatment and RA severity. <h3>Results</h3> a total of 204 RA were included. The mean age of the patients was 50.338±12.428 years. Sex-ratio: 0.13. The mean duration disease was 10.259±8.232 years. 43% of patients had extaarticular manifestations: 43%. The DAS vs-28 =4.615±1.440. HAQ =1.140±0.821.0. The ACPA rate was 229.855±241.902. Sharp mean: 112.995±93.965. 65.7% patients were treated by methotrexate. 32.8% by biological. 77, 4% patients were under corticoids. The periodontitis frequency was 37.3% (51.1% related to the porphyromonas gingivalis (PG). The tooth loss frequency was 31, 4%.the comparison of the subjects with periodontitis and patients without it showed no significant differences. the comparison of the patients with severe periodontitis and those without showed: age p=0.0004, menopause p=0.002, DAS p 0.47, Sharp p=0.06, HAQ p=0.95. <h3>Conclusions</h3> These results suggest a high prevalence of periodontitis during RA, PG is often responsible. The tooth loss frequency is also high. There is no correlation between periodontitis and RA severity and no relationship between PD and RA treatment. On the other hand periodontitis severity is related to the age and the menopause. <h3>Disclosure of Interest</h3> None declared
Hypoxia Inducible Factor 1á (HIF-1á) Regulates CD20 Expression in Lymphoma Cells: Possible Implications for Rituximab Based Therapy in Diffuse Large B Cell Lymphoma (DLBCL).
Authors: Sairah Ahmed, Andrew M. Evens, Savita Bhalla, Amareshwar Singh, Crystal James, Shuo Yang, Sheila Prachand, Danijela Dokic, Randy D. Gascoyne, Jane N. Winter, Paul T Schumacker, Leo I. Gordon
Journal: Blood (2009)
Measurement of β-isomerized C-terminal telopeptide of type I collagen in patients with POEMS syndrome: diagnostic, prognostic, and follow-up utilities
Authors: X Huang, C Zhang, C Wang, Q Cai, X Cao, H Cai, L Zhang, J Feng, D Zhou, J Li
Journal: Blood Cancer Journal (2016)

Measurement of β-isomerized C-terminal telopeptide of type I collagen in patients with POEMS syndrome: diagnostic, prognostic, and follow-up utilities a Comparisons between patients with higher and lower levels of serum β-CTX at baseline.b Castleman's disease was diagnosed in 16 of 25 patients who underwent lymph node biopsies.c Novel-agent group should include IMiDs (thalidomide and lenalidomide) and PIs (bortezomib); the others group included those patients using conventional chemotherapy (that is, CHOP).
SP0132 60 Years of Radiosynoviorthesis - State of The Art
Authors: W.U. Kampen
Journal: Annals of the Rheumatic Diseases (2016)

Since its first description in 1952, radiosynoviorthesis (RSO) is performed as a local treatment of synovitis in patients with inflammatory joint disease by intraarticular injection of beta-emitting radiocolloides. The radioactive particles are phagocytized by the superficial type-A synoviocytes and the local high-energy beta radiation with a therapeutic range of only a few millimetres results in a coagulation necrosis of the superficial synovial layers. The necrotic tissue is then repelled, the respective area is demarcated by a pronounced inflammatory reaction and finally a new synovial membrane is regenerated. Clinically, a significant reduction of both joint effusion and articular pain is noted with a consecutive improved mobility. Apart from its classical indication Rheumatoid Arthritis, RSO can be used to treat each kind of synovitis, regardless of the underlying pathology. The indication for RSO should be discussed in line with an interdisciplinary treatment regimen in cooperation between the nuclear medicine physician and a clinician experienced in rheumatology or orthopaedics, dependant on the respective patient. Clinical results with significant pain reduction and improved joint motion are achieved in approx. 60–80% of all joints treated are published in several randomized, controlled studies on evidence level Ib in patients with rheumatoid Arthritis. The treatment is cost-effective and safe, assuming a proper patient selection and a skilful injection technique. Local complications are very rare with an overall rate of 1‰ and less. This presentation will give an overview of the different indications for RSO, the pretherapeutic examinations and prerequisites necessary for patient selection, the procedure of the treatment itself with special aspects of radiation protection and imaging. Finally, possible side effects and complications with treatment strategies will be discussed. <h3>Disclosure of Interest</h3> None declared
Impact of Relapse after Allogeneic Hematopoietic Stem Cell Transplant on Subsequent Outcome in Patients with Chronic Myeloid Leukemia: A Better Understanding through Multi-State Modeling.
Authors: Cesare Guglielmi, Marta Fiocco, Ronald Brand, Eduardo Olavarria, Simona Iacobelli, Hein Putter, Dietger W. Niederwieser, T.M. de Witte, Alois Gratwohl
Journal: Blood (2006)
PTU-126 High Incidence of Oesophageal Dysmotility and Increased Inspiratory Gastro-Oesophageal Pressure Gradients in Patients with Unexplained Respiratory Symptoms
Authors: JM Burke, W Jackson, PW Waudby, AH Morice
Journal: Gut (2016)

<h3>Introduction</h3> It has been suggested that reflux and aspiration are common precipitants in respiratory diseases such as cough, asthma and Chronic Obstructive Pulmonary Disease. An excess of acid in these patients has been demonstrated by conventional pH monitoring, but correlation with symptoms are relatively poor. We have previously hypothesised that oesophageal dysmotility leading to both acid and non-acid aspiration may be an important etiological mechanism. Studies have also highlighted the importance of the gastro-oesophageal pressure gradient (GOPG) in the prevalence of reflux.<sup>1</sup> <h3>Methods</h3> High Resolution Oesophageal Manometry (HRM) was performed in 121 patients, 61 of whom presented primarily with unexplained respiratory symptom and complained predominantly of chronic cough (50), or breathlessness (11). An age and sex matched control group was chosen from patients presenting with suspected gastro-oesophageal reflux disease (GORD). The HRM findings of 61 patients (38 female), mean age 56 (range 18–81) with respiratory symptoms were compared with those of 60 suspected GORD patients (39 female), mean age 57, (range 19–81). <h3>Results</h3> Mean lower oesophageal sphincter (LOS) and upper oesophageal sphincter (UOS) resting pressures were similar between the two groups. There were fewer intact swallows in the respiratory group compared to those of the GORD group (42% vs 57%, P = 0.03). Intraoesophageal pressure was significantly lower during inspiration in the respiratory group compared to those of the GORD group (-11.5mmHg vs -8.7, p = 0.001). Consequently, there was a significantly higher GOPG was found in respiratory patients compared to those of the GORD group (46 mmHg vs 33 mmHg, p &lt; 0.01). <h3>Conclusion</h3> Using High Resolution Oesophageal Manometry, we have demonstrated a higher prevalence of oesophageal dysmotility in patients with unexplained respiratory symptoms than those presenting with typical GORD. Moreover, we have shown that those with unexplained respiratory symptoms exhibit higher inspiratory GOPGs and greater LOS peak contractions possibly stimulating an afferent vagal cough response. <h3>Reference</h3> 1 Ayazi S, DeMeester SR, <i>et al</i>. Thoracic-abdominal pressure gradients during the phases of respiration contribute to gastroesophageal reflux disease. <i>Digestive Disease and Sciences</i> 2011;<b>56</b>:1718–22. <h3>Disclosure of Interest</h3> None Declared
Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials
Authors: Ruth M Clifford, Pauline Robbe, Susanne Weller, Adele T Timbs, Michalis Titsias, Adam Burns, Maite Cabes, Reem Alsolami, Christopher Yau, Angela Hamblin, Joanne Mason, Melanie Oates, Andrew Pettitt, Chris Holmes, Peter Hillmen, Jenny Taylor, Samantha JL Knight, Anna Schuh
Journal: Blood (2014)
Early prevention of trauma-related infection/sepsis
Authors: Xiao-Yuan Ma, Li-Xing Tian, Hua-Ping Liang
Journal: Military Medical Research (2016)

Trauma still represents one of the major causes of death worldwide. Despite the reduction of post-traumatic sepsis over the past two decades, the mortality of septic trauma inpatients is still high (19.5–23 %). Early prevention of sepsis development can aid in the subsequent treatment of patients and help improve their outcomes. To date, the prevention of trauma-related infection/sepsis has mainly included infection prevention (e.g., surgical management, prophylactic antibiotics, tetanus vaccination, immunomodulatory interventions) and organ dysfunction prevention (e.g., pharmaceuticals, temporary intravascular shunts, lung-protective strategies, enteral immunonutrition, acupuncture). Overall, more efficient ways should be developed to prevent trauma-related infection/sepsis.
O045 : Bioactive lipids in the human liver in ‘Common NAFLD’ and ‘PNPLA3 NAFLD’
Authors: P. Luukkonen, Y. Zhou, S. Sädevirta, M. Oresic, T. Hyötyläinen, M. Orho-Melander, J. Arola, M. Leivonen, H. Yki-Järvinen
Journal: Journal of Hepatology (2015)